title: Immunomodulatory and hepatoprotective effects of in vivo treatment with free radical scavengers.
abstract: The hepatoprotective and immunomodulatory effects of silymarin and amino-imidazol-carboxamid-phosphate were studied in 60 patients with compensated alcoholic cirrhosis of the liver in a one month double blind clinical trial. Treatment with both drugs normalized the elevated levels of aspartate aminotransferase, alanine aminotransferase and serum bilirubin, markedly reduced the high level of gamma-glutamyl transferase, increased lectin-induced lymphoblasttransformation, decreased the percentage of CD8+ cells and suppressed lymphocytotoxicity. None of these changes occurred in the placebo-treated group. Thus the hepato-protective effects of silymarin and amino-imidazol-carboxamid-phosphate are accompanied by changes in parameters of cellular immunoreactivity of the treated patients.
authors.affiliation: Second Department of Medicine, Semmelweis University Medical School, Budapest, Hungary.
authors.forename: I
authors.initials: I
authors.lastname: Láng
authors.forename: K
authors.initials: K
authors.lastname: Nékám
authors.forename: G
authors.initials: G
authors.lastname: Deák
authors.forename: G
authors.initials: G
authors.lastname: Müzes
authors.forename: R
authors.initials: R
authors.lastname: Gonzales-Cabello
authors.forename: P
authors.initials: P
authors.lastname: Gergely
authors.forename: G
authors.initials: G
authors.lastname: Csomós
authors.forename: J
authors.initials: J
authors.lastname: Fehér
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use; D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000620:Aminoimidazole Carboxamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000975:Antioxidants / Q000627:therapeutic use; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008104:Liver Cirrhosis, Alcoholic / Q000097:blood / Q000188:drug therapy* / Q000201:enzymology / Q000276:immunology; D008213:Lymphocyte Activation / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012838:Silymarin / Q000627:therapeutic use*; D016176:T-Lymphocyte Subsets / Q000187:drug effects / Q000473:pathology; D005723:gamma-Glutamyltransferase / Q000097:blood
chemical_list: D000276:Adjuvants, Immunologic; D000975:Antioxidants; D010919:Placebos; D012838:Silymarin; D000620:Aminoimidazole Carboxamide; C028212:aminoimidazole carboxamide phosphate; D005723:gamma-Glutamyltransferase; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin